Context

In 2001 the FDA approved nesiritide for the treatment of acutely decompensated heart failure. As a potent intravenous vasodilator, nesiritide reduces cardiac filling pressures leading to symptomatic improvement in patients with acutely decompensated heart failure.1,–,4 However, this drug remains heavily debated even years after its approval, mainly because of a lack of substantial long-term safety data.5 In light of this evidence, the manufacturer gathered a panel of experts in 2005 in order to address this issue. One of the recommendations of the panel was to conduct a clinical trial on …